Search results for: “Biotalys”
-
Biotalys Reports Full-Year 2025 Financial Results and Business Highlights
Annual Results & Strategic Outlook Biotalys Announces 2025 Financial Results and Strategic Pivot Toward Commercial Readiness EPA Approval of EVOCA™ Validates AGROBODY™ Platform for Sustainable Crop Protection Year-End Cash €8.0 Million Financial Runway End of May 2026 Regulatory Status U.S. EPA Approved Biotalys (Euronext: BTLS) has announced its consolidated financial results for 2025, highlighting a…
-
Biotalys Announces Intention to Strategically Refocus its Activities to Prioritize Lead Assets and Reduce Annual Cash Burn
Summary: Biotalys (Euronext: BTLS) has announced a strategic refocus to prioritize its most advanced protein-based biocontrol programs, including EVOCA NG and BioFun-6. The initiative is designed to reduce total cash burn by €20 million through 2028, streamlining operations and right-sizing the organization to accelerate the path toward commercializing its precision biocontrol pipeline. Biotalys Announces Strategic…
-
Biotalys Announces Intention to Strategically Refocus its Activities to Prioritize Lead Assets and Reduce Annual Cash Burn
Summary: Biotalys has announced a strategic refocus to concentrate resources on its most advanced protein-based biocontrol programs, including EVOCA NG and BioFun-6. This restructuring aims to reduce total cash burn by €20 million through 2028, streamlining operations and right-sizing the organization to accelerate the path to commercialization and long-term value creation. Biotalys Proceeds with Strategic…
-
Biotalys Announces Intention to Strategically Refocus its Activities to Prioritize Lead Assets and Reduce Annual Cash Burn
Summary: Biotalys has announced a strategic refocus to prioritize its most advanced protein-based biofungicide programs, including EVOCA NG and BioFun-6. To streamline operations and extend its financial runway, the company is suspending early-stage activities and reducing its workforce by 30 employees. This restructuring is expected to reduce total cash burn by €20 million through the…
-
Biotalys Receives Regulatory Approval by U.S. EPA for EVOCA
Biotalys has achieved a historic milestone with the announcement that it has received regulatory approval from the U.S. EPA for EVOCA™. This marks the first protein-based biofungicide of its kind to secure such approval, validating the company’s AGROBODY™ technology and paving the way for sustainable protection of high-value fruits and vegetables. Biotalys Receives Regulatory Approval…
-
Biotalys Receives Regulatory Approval by U.S. EPA for EVOCA
Biotalys (Euronext: BTLS) is excited to announce it has received regulatory approval from the U.S. Environmental Protection Agency (EPA) for its first biofungicide, EVOCA™*. This product was developed using Biotalys’ AGROBODY™ technology platform and is the first protein-based biofungicide of its kind to be approved by the EPA. EVOCA is a precision biocontrol solution with…
-
Biotalys EVOCA Receives Historic EPA Approval as First Protein-Based Biofungicide
Biotalys has achieved a monumental regulatory milestone with the U.S. EPA approval of EVOCA™, the first protein-based biofungicide of its kind. This approval validates the company’s proprietary AGROBODY™ technology platform and paves the way for a new generation of sustainable crop protection tools that offer a novel mode of action against resistance-prone fungal diseases. Biotalys…
-
Biotalys Reports Progress in the Regulatory Review of EVOCA in both US and EU
Biotalys Advances Toward Regulatory Milestones for EVOCA™ in the United States and Europe Biotalys, a next-generation Agricultural Technology (AgTech) company based in Belgium, has announced key progress in the regulatory approval process for its groundbreaking protein-based biocontrol product, EVOCA™. This marks a major step forward in the company’s mission to revolutionize crop protection through sustainable,…